Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of ATH434 in multiple system atrophy. …
Alterity secures option underwriting as it prepares for pivotal MSA trial
August 31, 2026 Australian Biotech
Latest Video
New Stories
-
Alterity secures option underwriting as it prepares for pivotal MSA trial
August 31, 2026 - - Australian Biotech -
Avecho resumes pivotal insomnia trial recruitment after positive interim review
August 31, 2026 - - Australian Biotech -
Tetratherix sends first commercial polymer shipment to United States
August 31, 2026 - - Australian Biotech -
Expansion opens PBS access for more with advanced cancer, but it took a long time
August 31, 2026 - - Latest News -
A decade is more than enough - the case for term limits on advisory committees
August 31, 2026 - - Latest News -
September agenda puts cancer drugs, RSV prevention and ADHD access in focus
August 31, 2026 - - Latest News -
Funding brings a new targeted treatment for Australians with lupus kidney disease
August 31, 2026 - - Latest News